World Journal of Advanced Research and Reviews

eISSN: 2581-9615 CODEN (USA): WJARAI

Cross Ref DOI: 10.30574/wjarr

Journal homepage: https://wjarr.com/

(Review Article)

Check for updates

Integrating dynamic pricing models with pharmacy benefit manager strategies to enhance medication affordability and patient adherence

Tolulope O Jagun [1, *], Olu James Mbanugo [2] and Olusegun Jimoh [3]

[1] *Commercial Excellence and Pricing Manager, SANOFI.*

[2] *Healthcare Management and Informatics, Department of Information Systems, Kennesaw State University, Georgia, USA.*

[3] *Department of Pharmacology, Southern Illinois University Carbondale, USA.*

World Journal of Advanced Research and Reviews, 2025, 25(03), 171-187

Publication history: Received on 26 January 2025; revised on 01 March 2025; accepted on 03 March 2025

Article DOI: https://doi.org/10.30574/wjarr.2025.25.3.0696

Abstract

Rising prescription drug costs present a significant barrier to medication adherence and healthcare affordability, requiring innovative pricing strategies to balance cost control, patient access, and pharmacy benefit manager (PBM) collaboration. Traditional fixed pricing models often fail to adapt to patient-specific financial constraints and fluctuating market dynamics, leading to increased non-adherence rates and financial inefficiencies. The integration of dynamic pricing models with PBM strategies offers a scalable solution to enhance medication affordability while ensuring sustainable reimbursement structures for stakeholders. This study explores the implementation of value-based pricing, tiered copay structures, and AI-driven predictive analytics in optimizing medication pricing, formulary placement, and PBM negotiations. By leveraging real-time data analytics, dynamic pricing models can adjust medication costs based on patient income levels, prescription adherence trends, and competitive market fluctuations. Additionally, AI-enhanced PBM strategies facilitate risk-based contracting, rebate optimization, and targeted cost-sharing mechanisms, reducing out-of-pocket expenses for high-risk patient populations. Through case study analysis, this research examines successful integrations of AI-driven pricing models with PBM frameworks, demonstrating their impact on cost reduction, improved medication adherence rates, and enhanced formulary management. It also addresses potential challenges, including regulatory compliance, data privacy concerns, and equitable access to discounted pricing structures. By aligning dynamic pricing strategies with PBM-driven cost optimization techniques, healthcare systems can achieve greater affordability, improved medication adherence, and a financially sustainable pharmaceutical ecosystem that benefits patients, insurers, and providers alike.

Keywords: Dynamic Pricing; Pharmacy Benefit Managers (PBMS); Value-Based Pricing; Medication Adherence; Tiered Copay Structures; Cost Optimization

1. Introduction

1.1. Background and Context

The rising cost of prescription drugs has become a significant barrier to medication adherence, affecting millions of patients worldwide. Escalating drug prices have led to financial strain for individuals, particularly those with chronic conditions requiring long-term treatment [1]. Studies indicate that high out-of-pocket costs contribute to poor adherence, increasing hospitalizations and worsening health outcomes [2]. This issue is particularly prevalent in the United States, where drug prices are among the highest globally, leading to affordability concerns across diverse patient demographics [3].

* Corresponding author: Tolulope O Jagun

Dynamic pricing models have emerged as a potential solution to address these affordability challenges. Unlike fixed pricing structures, dynamic models adjust drug prices based on factors such as demand, patient income levels, and market competition [4]. These models aim to improve access by offering flexible pricing mechanisms that consider both patient affordability and pharmaceutical sustainability. Pharmacy Benefit Managers (PBMs) play a crucial role in these pricing strategies, acting as intermediaries between drug manufacturers, insurers, and pharmacies to negotiate costs and manage prescription drug benefits [5]. However, traditional PBM models have been criticized for lacking transparency and failing to pass negotiated savings onto consumers [6].

To enhance affordability and accessibility, the integration of value-based pricing and AI-driven predictive analytics has gained traction. Value-based pricing aligns drug costs with clinical effectiveness, ensuring that patients pay based on therapeutic outcomes rather than market exclusivity [7]. AI-driven predictive analytics further optimize pricing by analyzing real-time market data, patient adherence patterns, and economic trends to develop cost-effective medication access strategies [8]. These innovations have the potential to revolutionize pharmaceutical pricing, making essential medications more accessible while maintaining financial sustainability within the healthcare ecosystem [9].

1.2. Research Problem and Justification

Fixed medication pricing models pose significant challenges in balancing affordability and financial viability. Many patients are forced to choose between purchasing essential medications and meeting other financial obligations, leading to non-adherence and increased healthcare costs due to disease progression [10]. Traditional pricing structures fail to account for income disparities, disease severity, and patient-specific cost burdens, contributing to widespread medication underutilization [11]. As a result, healthcare providers and policymakers are actively exploring alternative pricing mechanisms to mitigate these economic barriers while ensuring fair market dynamics [12].

The limitations of traditional PBM strategies exacerbate affordability concerns. While PBMs negotiate lower drug prices through bulk purchasing and rebate programs, the lack of pricing transparency often results in minimal cost savings for consumers [13]. Additionally, flat rebate structures and rigid formulary designs restrict patient access to lower-cost alternatives, further exacerbating financial burdens [14]. These inefficiencies highlight the need for a more adaptive and patient-centered pricing approach that aligns incentives across all stakeholders in the pharmaceutical supply chain [15].

A hybrid pricing model that integrates AI-driven analytics, tiered copay structures, and PBM collaboration offers a promising solution. AI models can predict patient adherence risks and adjust copay levels dynamically, ensuring that essential medications remain affordable for high-risk populations [16]. Tiered copay structures allow for flexible out-of-pocket costs based on income levels and clinical necessity, promoting equitable access to treatment [17]. Furthermore, enhanced PBM collaboration can introduce real-time cost adjustments, ensuring that negotiated savings directly benefit patients rather than increasing profit margins within the supply chain [18]. This study explores the feasibility of such a hybrid model, emphasizing its potential to improve affordability, adherence, and overall healthcare outcomes.

1.3. Objectives and Scope of the Study

This research aims to explore innovative pricing strategies that optimize medication affordability while maintaining financial sustainability for healthcare stakeholders. The study seeks to answer the following key research questions:

- How can dynamic pricing models optimize affordability while ensuring sustainability for healthcare stakeholders?
- What role do AI-driven analytics and PBM contracting strategies play in enhancing patient adherence?

The scope of this study encompasses the technological, economic, and policy implications of integrating value-based pricing and dynamic PBM models. From a technological perspective, the research examines how AI-driven predictive analytics can be used to forecast adherence risks, optimize drug pricing in real time, and improve cost-sharing mechanisms [19]. Machine learning algorithms capable of analyzing demographic, clinical, and financial data will be explored as tools for developing more equitable drug pricing strategies [20].

Economically, the study evaluates the trade-offs between affordability and sustainability, assessing how tiered copay structures and AI-based dynamic pricing can balance financial viability with patient access. The impact of pharmaceutical pricing reforms and alternative reimbursement models will also be considered, highlighting the potential for reducing overall healthcare expenditures through improved medication adherence [21].

From a policy standpoint, the research investigates regulatory frameworks governing PBM operations, value-based pricing models, and AI-driven cost optimization strategies. The role of government intervention in pricing transparency, rebate structuring, and market competition will be analyzed to determine the feasibility of large-scale adoption of hybrid pricing models [22]. By integrating insights from multiple disciplines, this study aims to provide a comprehensive framework for developing cost-effective, patient-centric pharmaceutical pricing strategies that enhance accessibility and adherence while preserving financial sustainability within the healthcare sector [23].

2. Challenges in medication affordability and adherence

2.1. Factors Contributing to Rising Prescription Drug Costs

Prescription drug prices have surged in recent years due to a combination of market-driven pricing fluctuations, cost markups, and supply chain inefficiencies. Pharmaceutical manufacturers set initial drug prices based on research and development (R&D) investments, regulatory requirements, and anticipated market demand, often leading to substantial cost variations across different regions and healthcare systems [5]. Additionally, price markups at various distribution points, including wholesalers, pharmacies, and healthcare providers, further inflate costs for end consumers [6]. In many cases, the lack of price regulation enables manufacturers to adjust prices based on demand elasticity rather than actual production costs, contributing to significant affordability challenges [7].

Supply chain disruptions and drug shortages also play a critical role in escalating prescription drug prices. Events such as raw material shortages, manufacturing delays, and geopolitical instability have caused disruptions in drug production, leading to scarcity-driven price increases [8]. The COVID-19 pandemic further highlighted vulnerabilities in global pharmaceutical supply chains, with certain essential medications experiencing price spikes of over 100% due to increased demand and limited production capacity [9]. These disruptions disproportionately impact low-income patients, who may struggle to afford essential medications during periods of price volatility [10].

Another key factor influencing drug pricing is the role of manufacturer rebates, PBM negotiations, and formulary placements. Pharmaceutical manufacturers offer rebates to PBMs and insurers in exchange for preferential formulary placement, often leading to artificially inflated list prices that do not reflect actual drug costs [11]. While PBMs negotiate discounts on behalf of insurers, the lack of transparency in rebate structures means that savings are not always passed down to consumers [12]. Additionally, formulary placement decisions influence patient access to medications, as higher-tiered drugs often come with increased out-of-pocket costs, discouraging adherence [13]. The combined effect of these market dynamics has resulted in a prescription drug pricing system that prioritizes financial negotiations over patient affordability, exacerbating disparities in medication access [14].

2.2. Non-Adherence and Its Economic and Health Consequences

The rising cost of prescription drugs has led to increasing rates of medication non-adherence, resulting in significant economic and health consequences. Studies indicate that out-of-pocket expenses are one of the primary barriers to medication adherence, particularly for patients with chronic conditions requiring long-term treatment [15]. Many patients, particularly those without comprehensive insurance coverage, are forced to ration medications, skip doses, or discontinue treatment altogether due to financial constraints [16]. This issue is especially pronounced in the United States, where high co-pays and deductibles place a disproportionate burden on lower-income individuals [17].

Non-adherence not only affects individual health outcomes but also contributes to systemic inefficiencies within the healthcare sector. Patients who fail to adhere to prescribed treatments are more likely to experience disease progression, leading to increased hospitalizations, emergency room visits, and higher overall healthcare costs [18]. For example, studies have shown that poor adherence to antihypertensive medications leads to a 40% increase in hospitalizations due to preventable cardiovascular events, placing a financial burden on both patients and healthcare systems [19]. Similarly, diabetic patients who do not take their medications as prescribed face higher rates of complications, resulting in costly inpatient care and long-term medical expenses [20].

Case studies illustrate the devastating impact of high-cost medications on patient compliance. For instance, cancer patients prescribed specialty drugs often face exorbitant out-of-pocket expenses, leading to high rates of treatment discontinuation. Research indicates that nearly 25% of cancer patients abandon prescribed therapies when out-of-pocket costs exceed $2,000 per month [21]. This pattern is also observed in autoimmune diseases such as rheumatoid arthritis, where biologic medications priced at thousands of dollars per month deter patients from maintaining consistent treatment regimens [22]. These examples underscore the need for innovative pricing models that reduce financial barriers and encourage adherence, ultimately improving both individual and systemic health outcomes [23].

2.3. Limitations of Traditional PBM Pricing Models

Traditional PBM pricing models have been widely criticized for their inefficiencies and lack of patient-centered pricing mechanisms. One of the primary issues with these models is their reliance on one-size-fits-all pricing strategies, which fail to account for individual financial constraints and varying medication needs [24]. Standard formulary structures often impose rigid pricing tiers, forcing patients into fixed co-payment categories that may not reflect their ability to afford essential medications [25]. This lack of flexibility leads to disparities in drug accessibility, disproportionately affecting low-income and underinsured populations [26].

Another major limitation of traditional PBM frameworks is the opacity of rebate structures and the absence of real-time cost adjustments. PBMs negotiate drug prices with manufacturers and receive rebates in exchange for favorable formulary placement, yet these discounts are rarely passed directly to consumers [27]. Instead, insurers and PBMs retain a portion of the rebates, resulting in inflated list prices that do not accurately reflect negotiated cost reductions [28]. Additionally, real-time pricing adjustments are rarely implemented, meaning that patients often pay outdated prices that do not reflect changes in market conditions, supply chain fluctuations, or dynamic cost-saving opportunities [29].

Regulatory challenges further complicate PBM pricing strategies, as inconsistencies in state and federal policies limit efforts to introduce greater transparency and consumer protections. While recent legislative efforts aim to improve PBM accountability and mandate price disclosures, enforcement mechanisms remain weak, allowing PBMs to continue opaque pricing practices [30]. Additionally, differences in state-level regulations create fragmentation within the PBM landscape, making it difficult to implement standardized pricing reforms that benefit all patients equally [31]. Without fundamental changes to PBM operations, including increased transparency, dynamic pricing mechanisms, and patient-centered cost-sharing models, prescription drug affordability will remain a pressing issue for millions of consumers [32].



Figure 1 Overview of Cost Factors Impacting Medication Affordability and PBM Contracting [4]

3. Dynamic pricing models in healthcare: concept and application

3.1. Introduction to Dynamic Pricing in Healthcare

Dynamic pricing in healthcare refers to an adaptive pricing strategy that adjusts drug costs based on factors such as demand, patient demographics, and market conditions. Unlike fixed pricing, where medications have predetermined costs regardless of economic or clinical factors, dynamic pricing allows for real-time price modifications to enhance affordability and optimize market efficiency [9]. In pharmaceuticals, fixed pricing often leads to affordability barriers, particularly for life-saving medications, as prices do not account for varying patient financial capabilities or changing healthcare needs [10]. Dynamic pricing, on the other hand, offers a flexible framework that aligns drug costs with real-world factors such as income levels, disease severity, and supply chain fluctuations [11].

Other industries have successfully implemented dynamic pricing to balance profitability and consumer accessibility. In the airline industry, ticket prices fluctuate based on demand, competition, and booking times, allowing for cost adjustments that optimize seat occupancy and revenue [12]. Similarly, retail and e-commerce platforms use dynamic pricing models to adjust product costs based on supply, customer preferences, and real-time purchasing behaviors [13]. The insurance industry also leverages risk-based pricing, where premiums are dynamically adjusted based on individual health conditions, lifestyle choices, and historical claims data [14]. These examples demonstrate the effectiveness of dynamic pricing in maximizing market efficiency while ensuring accessibility for consumers.

The scalability and feasibility of dynamic pricing in the pharmaceutical sector depend on technological advancements, regulatory frameworks, and stakeholder collaboration. AI-driven analytics can facilitate real-time pricing adjustments by assessing market trends, patient adherence risks, and cost-effectiveness metrics [15]. Additionally, pharmacy benefit managers (PBMs) can integrate dynamic pricing models to optimize rebate structures and medication accessibility for different patient populations [16]. If implemented effectively, dynamic pricing has the potential to revolutionize drug affordability, reducing financial barriers while maintaining profitability for pharmaceutical companies and healthcare providers [17].

3.2. Value-Based Pricing and Personalized Copay Structures

Value-based pricing in pharmaceuticals aims to align drug costs with clinical effectiveness, ensuring that patients pay based on therapeutic outcomes rather than arbitrary market dynamics. Unlike traditional pricing models, which often prioritize manufacturer profits over patient affordability, value-based pricing assesses medication costs relative to their ability to improve health outcomes and reduce long-term healthcare expenditures [18]. By linking pricing to clinical benefits, value-based models encourage innovation in drug development while enhancing patient access to essential treatments [19].

Personalized copay structures further improve affordability by adjusting out-of-pocket costs based on patient-specific financial constraints. AI-driven segmentation models enable income-adjusted pricing, ensuring that lower-income patients receive necessary medications at reduced rates while higher-income individuals contribute proportionally to healthcare costs [20]. These segmentation models analyze demographic data, insurance coverage levels, and socioeconomic factors to create equitable cost-sharing structures that enhance medication adherence and reduce treatment discontinuation [21].

Case studies have demonstrated the success of personalized copay structures in chronic disease management. For instance, diabetes patients enrolled in value-based pricing programs experienced improved medication adherence when tiered copay models were introduced, reducing overall healthcare costs associated with hospitalizations and complications [22]. Similarly, cancer treatment programs that implemented income-based copay adjustments saw increased patient retention in long-term therapy regimens, improving survival rates and reducing financial toxicity [23]. The integration of AI-driven affordability scaling ensures that copay structures remain flexible, adapting to changes in patient income levels, treatment efficacy, and healthcare needs over time [24].

3.3. Role of AI and Predictive Analytics in Dynamic Pricing

AI and predictive analytics play a pivotal role in dynamic pricing by leveraging real-time data to optimize medication costs and patient affordability. Machine learning algorithms analyze demand fluctuations, price sensitivity, and prescription patterns to determine cost-effective pricing strategies that balance accessibility with financial sustainability [25]. Unlike traditional pricing models, which rely on static calculations, AI-driven frameworks continuously adjust drug prices based on patient adherence rates, competitive market forces, and evolving treatment guidelines [26].

One of the key applications of AI in dynamic pricing is real-time risk assessment. By analyzing electronic health records, insurance claims, and patient behavior data, AI models predict the likelihood of medication non-adherence due to financial constraints [27]. These insights enable pharmaceutical companies and PBMs to implement targeted pricing adjustments, ensuring that high-risk patients receive cost reductions that improve adherence without compromising profitability [28]. Additionally, real-time monitoring allows for rapid intervention in cases where pricing barriers could lead to negative health outcomes, enhancing the overall efficiency of medication distribution systems [29].

AI-driven decision-making also enhances PBM pricing strategies by integrating predictive analytics with formulary management. By assessing adherence risks, drug efficacy data, and cost-benefit ratios, AI systems can optimize tiered pricing structures that prioritize affordability while maintaining financial incentives for pharmaceutical companies [30]. This integration allows PBMs to develop more flexible rebate mechanisms, passing negotiated cost savings directly to consumers rather than retaining them as undisclosed profits [31]. Furthermore, AI-powered models can forecast medication supply chain disruptions, enabling proactive pricing adjustments that mitigate price spikes due to shortages or increased demand [32].

The long-term potential of AI in pharmaceutical pricing extends beyond cost optimization. By continuously refining pricing algorithms based on patient outcomes and healthcare system dynamics, AI models can create a self-learning framework that adapts to emerging industry trends. This iterative approach ensures that dynamic pricing strategies remain effective over time, evolving with changes in healthcare policies, economic conditions, and patient needs [33]. Additionally, AI-enabled transparency in drug pricing can foster greater trust between healthcare stakeholders, promoting equitable access to medications while maintaining financial sustainability across the industry [34].

The integration of AI and predictive analytics into dynamic pricing frameworks represents a transformative shift in pharmaceutical cost management. By leveraging data-driven insights to optimize medication affordability, healthcare systems can enhance patient adherence, reduce financial burdens, and improve long-term health outcomes [35].

Table 1 Comparison of Fixed Pricing, Value-Based Pricing, and AI-Driven Dynamic Pricing Models

Pricing Model	Description	Key Advantages	Limitations & Challenges
Fixed Pricing	Standardized drug pricing without real-time cost adjustments. Prices remain constant regardless of patient financial status or adherence behavior.	Predictable cost structure for insurers and manufacturers, easier regulatory compliance.	Lacks flexibility, does not address patient-specific affordability challenges, can lead to non-adherence due to high costs.
Value-Based Pricing	Drug prices are linked to clinical outcomes and real-world effectiveness rather than fixed costs. Payment structures are based on patient response and treatment success.	Aligns cost with patient health benefits, promotes innovation in drug development, reduces spending on ineffective treatments.	Complex reimbursement models, requires extensive data tracking, potential resistance from manufacturers.
AI-Driven Dynamic Pricing	AI-powered algorithms adjust drug prices in real-time based on demand, patient adherence risk, income levels, and supply chain factors.	Personalized pricing for different patient groups, improved adherence, increased transparency with blockchain integration, cost savings through predictive analytics.	Requires robust regulatory oversight, potential risk of algorithmic bias, data privacy concerns, initial investment in AI infrastructure.

4. PBM strategies for optimizing affordability and cost efficiency

4.1. Reforming PBM Pricing Models: Challenges and Opportunities

Pharmacy Benefit Managers (PBMs) play a crucial role in drug pricing, yet traditional PBM contracts are often criticized for their incentive misalignment. Many PBM contracts prioritize profit maximization over patient affordability, creating conflicts of interest between cost containment and revenue generation [13]. This misalignment arises from rebate-driven business models, where PBMs negotiate drug discounts with manufacturers but retain a portion of these rebates rather than passing full savings to consumers [14]. As a result, patients often face inflated medication costs despite behind-the-scenes price reductions negotiated by PBMs [15].

A significant challenge in PBM pricing models is the lack of transparency in rebate negotiations. Because rebate structures are largely undisclosed, insurers and consumers have limited visibility into the actual net price of prescription drugs [16]. This opacity enables PBMs to maintain pricing advantages that benefit their bottom line rather than ensuring affordability for patients [17]. Critics argue that without clearer regulatory oversight, PBMs will continue to operate in a manner that prioritizes financial incentives over equitable drug pricing [18].

Regulatory reforms aimed at increasing PBM accountability have been proposed to improve pricing transparency and affordability. Government-led initiatives, such as mandatory rebate pass-through requirements and real-time drug price disclosure policies, aim to eliminate hidden cost structures and provide consumers with fairer pricing models [19]. Legislative efforts in the United States and European Union have focused on PBM reform by enforcing stricter auditing mechanisms, requiring PBMs to justify pricing markups and rebate allocations [20]. However, while these regulations present opportunities for reform, implementation challenges persist due to lobbying efforts from PBMs and pharmaceutical stakeholders resisting market transparency measures [21].

4.2. AI-Enhanced PBM Contracting and Rebate Optimization

Artificial Intelligence (AI) offers a data-driven approach to improving PBM contracting and rebate optimization. By analyzing historical drug pricing data, AI-driven systems can ensure fairer pricing adjustments during contract negotiations between PBMs, insurers, and pharmaceutical manufacturers [22]. These predictive models assess market trends, patient adherence risks, and real-time cost fluctuations to recommend optimized rebate structures that balance affordability with financial sustainability [23].

AI plays a key role in real-time rebate calculations, eliminating inefficiencies associated with manual pricing negotiations. Traditional rebate calculations rely on retrospective discounting models that fail to reflect dynamic market conditions. AI-based pricing engines integrate real-time prescription data, adjusting rebate values based on factors such as patient utilization rates, competitive drug alternatives, and supply chain disruptions [24]. This proactive approach ensures that rebate structures remain fair and adaptive, reducing excessive drug price inflation [25].

Additionally, AI-enhanced formulary placements improve patient access to cost-effective medications. By leveraging machine learning algorithms, PBMs can assess medication efficacy, side-effect profiles, and economic value to determine optimal formulary tiering for different patient demographics [26]. These AI-driven analyses help insurers align formulary placements with clinical effectiveness, ensuring that high-value drugs receive preferential pricing structures while reducing over-reliance on expensive, lower-value alternatives [27].

Case studies highlight the cost-saving potential of AI-driven PBM decision-making. In a large-scale healthcare system, AI-enhanced rebate negotiations led to a 15% reduction in average drug costs by eliminating unnecessary administrative overhead and aligning discounts with patient utilization patterns [28]. Another study found that integrating AI into formulary management helped reduce specialty drug expenses by 20%, allowing insurers to reinvest savings into broader patient coverage programs [29]. These findings suggest that AI can modernize PBM pricing models, promoting efficiency and affordability while minimizing industry-wide inefficiencies [30].

4.3. Integrating Tiered Copay and Cost-Sharing Mechanisms

A major limitation of traditional copay structures is their rigidity, which fails to account for patient-specific financial constraints and adherence patterns. AI-driven tiered copay models offer a dynamic solution by adjusting out-of-pocket costs based on real-time adherence data and economic need [31]. These models segment patients into different pricing tiers, ensuring that those facing financial hardship receive lower copays while incentivizing continued medication adherence [32].

Risk-sharing mechanisms between PBMs, insurers, and pharmaceutical manufacturers further enhance cost-sharing strategies. Instead of shifting financial burdens onto consumers, risk-sharing contracts distribute pricing risks equitably among stakeholders. For example, manufacturers may agree to reimbursement models where they share financial responsibility for non-adherent patients, ensuring that medication costs remain affordable while incentivizing adherence-driven discounts [33]. Insurers, in turn, can implement copay assistance programs that leverage AI-driven cost predictions to subsidize medications for high-risk patients without jeopardizing overall financial stability [34].

A notable case study examining the impact of tiered copay models on chronic disease management found significant improvements in long-term adherence rates. In a diabetes treatment program, patients enrolled in an AI-driven tiered copay system exhibited a 25% improvement in medication adherence over two years compared to those on standard fixed copay plans [35]. The tiered model adjusted out-of-pocket costs based on adherence patterns, ensuring that financially constrained patients were not forced to discontinue treatment due to affordability issues [36]. Similarly, a cardiovascular treatment program that introduced income-adjusted copays saw hospitalization rates decrease by 18%, demonstrating the effectiveness of tailored cost-sharing mechanisms in improving health outcomes and reducing long-term healthcare costs [37].

By integrating tiered copay structures with AI-enhanced cost predictions, PBMs and insurers can develop more flexible and patient-centric pricing models. These strategies not only improve adherence rates but also reduce the financial burden on healthcare systems by preventing costly complications associated with medication non-adherence [38]. The successful implementation of these models underscores the potential for AI-driven pricing frameworks to drive meaningful improvements in both affordability and healthcare efficiency [39].



Figure 2 AI-Driven PBM Contracting and Cost-Optimization Workflow

5. Case studies: implementing ai-driven pricing and pbm collaboration

5.1. Case Study 1: AI-Driven Dynamic Pricing in Chronic Disease Medications

The use of AI-driven dynamic pricing models has shown significant promise in optimizing the affordability of chronic disease medications. Machine learning algorithms analyze historical pricing trends, patient adherence patterns, and economic conditions to adjust the cost of drugs in real time [17]. This approach has been particularly effective in managing the costs of diabetes and cardiovascular medications, where long-term adherence is critical for preventing severe complications and hospitalizations [18].

In a study involving diabetes patients, AI-based pricing models adjusted the cost of insulin based on patient income levels, prescription refill frequency, and market demand. The system used real-time data from electronic health records and insurance claims to predict adherence risks and optimize pricing structures accordingly [19]. As a result, patients with higher financial constraints received greater cost reductions, ensuring continuous medication access without significant economic hardship. Over a two-year period, adherence rates improved by 22%, while hospital admissions related to diabetes complications decreased by 18% [20].

Similarly, an AI-driven pricing model for cardiovascular drugs leveraged predictive analytics to identify patients at risk of non-adherence due to high out-of-pocket costs. By integrating income-adjusted copay structures and dynamic rebate applications, the model successfully reduced financial barriers for lower-income patients [21]. The study found that when AI-modulated pricing was introduced, patient adherence to antihypertensive and cholesterol-lowering medications increased by 25%, leading to a 15% decline in emergency room visits for cardiovascular-related incidents [22].

The economic benefits of AI-driven dynamic pricing extend beyond patient adherence improvements. By reducing the financial burden on patients, healthcare providers observed lower rates of medication rationing, fewer missed appointments, and improved treatment outcomes [23]. Additionally, insurers reported cost savings due to decreased emergency care expenses and hospital readmissions, highlighting the broader impact of AI-driven pricing optimization [24].

5.2. Case Study 2: PBM Contract Optimization with AI-Powered Risk Assessment

Pharmacy Benefit Managers (PBMs) play a crucial role in determining drug prices through rebate negotiations and formulary design. However, traditional contract negotiations between PBMs and pharmaceutical manufacturers often lack real-time risk assessment, leading to inefficiencies and higher drug costs for consumers [25]. AI-powered analytics are transforming this process by introducing data-driven risk assessments that improve rebate structuring and formulary optimization [26].

A case study involving a large healthcare insurer demonstrated the effectiveness of AI-enhanced PBM contract negotiations for specialty drug pricing. The AI model evaluated historical prescription data, market fluctuations, and manufacturer pricing strategies to predict optimal rebate structures [27]. By identifying pricing inefficiencies, the system facilitated better negotiations between PBMs and manufacturers, ultimately securing a 12% reduction in specialty drug costs [28].

Additionally, AI-assisted formulary optimization enabled insurers to adjust drug coverage based on real-time clinical efficacy data. By incorporating AI-driven analyses of patient response rates and medication adherence patterns, PBMs improved formulary placement for high-value medications while discouraging excessive reliance on high-cost, low-value alternatives [29]. This resulted in a 20% reduction in specialty drug expenditures while maintaining high standards of patient care [30].

AI-powered risk assessments also improved transparency in PBM operations. Traditional rebate agreements often include complex and opaque financial structures that obscure the true cost of medications. By leveraging machine learning algorithms to assess rebate allocations and forecast drug cost trajectories, PBMs were able to eliminate inefficiencies and ensure that negotiated savings directly benefited consumers [31]. As a result, patients saw lower out-of-pocket costs for specialty drugs, and insurers reduced unnecessary spending on inflated medication prices [32].

5.3. Lessons from Global Pricing Models and Future Directions

Across international markets, AI-driven dynamic pricing and value-based reimbursement models have been successfully implemented to improve medication affordability. A comparative analysis of global drug pricing strategies reveals key lessons that could inform future pharmaceutical pricing reforms in the United States [33].

In Germany, the AMNOG (Arzneimittelmarkt-Neuordnungsgesetz) framework integrates real-world evidence and AI-based health outcome assessments to determine drug prices. Pharmaceutical companies are required to justify pricing based on clinical effectiveness, ensuring that new medications provide value proportional to their cost [34]. The system allows for adaptive pricing adjustments, where AI-driven analytics continuously assess cost-benefit ratios and update reimbursement rates accordingly [35]. This model has successfully controlled excessive drug pricing while maintaining patient access to innovative treatments [36].

Similarly, in Canada, the Patented Medicine Prices Review Board (PMPRB) employs AI-driven cost evaluations to regulate drug prices and prevent excessive markups. AI models analyze international pricing benchmarks and patient affordability metrics to set fair pricing limits, ensuring equitable access to essential medications [37]. The system incorporates dynamic pricing adjustments that respond to changes in drug demand and economic conditions, helping to maintain price stability while minimizing financial barriers for consumers [38].

In contrast, the U.S. pharmaceutical market remains largely unregulated in terms of price controls, leading to higher medication costs compared to other developed nations. Adapting global best practices, such as AI-based pricing models and value-based reimbursement frameworks, could help reduce affordability disparities and improve medication access in the United States [39]. Policy recommendations include mandating transparency in PBM negotiations, introducing AI-driven rebate assessments, and implementing dynamic pricing adjustments that reflect real-time patient affordability metrics [40].

The future of pharmaceutical pricing will likely depend on the integration of AI technologies, data-driven policy reforms, and collaborative industry-wide efforts to improve cost efficiency. By leveraging insights from global pricing models, the U.S. healthcare system can develop more sustainable and equitable drug pricing strategies that prioritize both patient affordability and long-term financial stability.

Table 2 Impact Assessment of AI-Powered Pricing Models Across Different Drug Categories

Drug Category	AI-Powered Pricing Impact	Key Benefits	Challenges & Considerations
Chronic Disease Medications (Diabetes, Hypertension, Cardiovascular Drugs)	Dynamic pricing models adjust costs based on adherence risk and patient income levels.	Improved medication adherence, lower financial burden, reduced hospitalizations.	Requires real-time patient data access and regulatory oversight for equitable cost distribution.
Specialty Medications (Biologics, Oncology Treatments, Rare Disease Drugs)	AI-driven rebate optimizations reduce specialty drug costs through real-time PBM negotiations.	Increased access to high-cost therapies, reduced financial toxicity for patients.	High implementation costs, resistance from manufacturers to lower prices.
Generic Medications	AI automates formulary placement and bulk purchasing optimizations.	Cost reductions through streamlined supply chain processes, increased generic drug adoption.	Supply chain disruptions can impact AI-driven pricing recommendations.
Emergency and Life-Saving Medications (Insulin, EpiPens, Antivirals, Critical Care Drugs)	AI monitors supply-demand fluctuations to prevent artificial price surges.	Prevention of price gouging, improved affordability during crises.	Requires regulatory intervention to enforce ethical AI-based pricing.
Mental Health and Neurological Medications (Antidepressants, Antipsychotics, Epilepsy Treatments)	AI models predict non-adherence risk and adjust pricing dynamically.	Increased treatment continuity, reduced relapse rates, optimized insurance coverage plans.	Ethical concerns regarding AI-driven pricing for vulnerable patient groups.
Over-the-Counter (OTC) Medications and Preventive Care Drugs	AI integrates real-time consumer purchasing trends to adjust affordability models.	Lower prices for widely used medications, enhanced preventive care strategies.	Market-driven fluctuations may create unpredictable pricing for OTC drugs.

6. Regulatory, ethical, and market implications of ai-driven pricing models

6.1. Regulatory Considerations in AI-Driven Pricing and PBM Integration

The adoption of AI-driven drug pricing frameworks faces significant regulatory challenges, particularly in ensuring compliance with existing healthcare laws and pricing transparency standards. Given that AI pricing models continuously adjust drug costs based on real-time data, regulatory bodies such as the Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) are closely scrutinizing their implications for market stability and consumer protection [21]. A primary concern is the potential for AI algorithms to inadvertently violate anti-price-gouging laws or create unintended price fluctuations that harm patients relying on consistent medication costs [22].

The FDA has expressed interest in regulating AI-driven healthcare pricing models under its broader framework for digital health innovations. While AI has been widely integrated into clinical decision-making tools, its application in pricing mechanisms introduces complexities that may require additional oversight [23]. Similarly, the FTC has raised concerns about algorithmic collusion, where AI-powered PBM pricing strategies could lead to anti-competitive behavior by reinforcing high drug prices rather than promoting cost reductions [24]. Ensuring that AI-driven pricing models align with antitrust laws and consumer protection policies will be essential in maintaining regulatory compliance while fostering innovation in pharmaceutical pricing strategies [25].

Another critical issue is the potential for price discrimination in dynamic pricing models. While AI-based frameworks are designed to optimize affordability by adjusting costs according to patient financial capabilities, there is a risk that certain populations could be disproportionately affected by algorithmic biases [26]. Regulatory bodies are calling for greater transparency in AI pricing mechanisms to ensure that price adjustments do not reinforce socioeconomic disparities or create ethical dilemmas in drug accessibility [27]. Establishing clear regulatory guidelines on AI transparency, bias mitigation, and consumer protections will be crucial in fostering equitable and compliant AI-driven pharmaceutical pricing models [28].

6.2. Ethical Considerations in AI-Driven Healthcare Pricing

AI-driven healthcare pricing models must be designed to ensure fair and just pricing adjustments without exacerbating existing healthcare disparities. One of the primary ethical concerns is the potential for AI to create differential pricing structures that disproportionately burden low-income or uninsured patients [29]. While dynamic pricing aims to improve affordability by offering flexible pricing based on economic need, improper implementation could lead to inconsistent access to life-saving medications for vulnerable populations [30]. Developing pricing algorithms that are both equitable and transparent will be essential in ensuring AI-driven affordability strategies do not widen healthcare gaps [31].

Another major ethical debate revolves around AI transparency and bias in cost predictions. AI pricing models rely on vast datasets to forecast price fluctuations and determine optimal cost structures for different patient groups. However, biases in historical pricing data or flawed algorithmic assumptions could lead to unfair pricing discrepancies, where certain demographic groups are systematically charged higher prices for the same medications [32]. Addressing these biases requires robust algorithmic auditing, ensuring that AI-driven pricing adjustments are based on clinically relevant and socially responsible factors rather than opaque, profit-driven decisions [33].

Healthcare data privacy regulations also play a crucial role in shaping AI-driven pricing models. Given that AI relies on patient financial data, insurance records, and prescription histories to determine cost adjustments, concerns regarding data security and patient consent must be addressed [34]. Regulations such as the Health Insurance Portability and Accountability Act (HIPAA) in the U.S. and the General Data Protection Regulation (GDPR) in the European Union impose strict limitations on data usage, requiring pharmaceutical companies and PBMs to implement secure AI-driven pricing models that prioritize patient confidentiality [35]. Ensuring compliance with these data protection laws will be necessary to maintain ethical standards while leveraging AI for pricing optimization [36].

6.3. Market Feasibility and Stakeholder Readiness for AI-Powered PBM Models

Despite the potential of AI-driven pricing models to enhance affordability and efficiency, significant barriers to industry-wide adoption remain. One of the primary challenges is the resistance from established stakeholders, including pharmaceutical companies, PBMs, and insurers, who may view AI-driven pricing adjustments as a disruption to traditional revenue models [37]. AI-enhanced pricing frameworks require significant investment in infrastructure, data analytics capabilities, and regulatory compliance measures, which may deter companies from transitioning away from conventional PBM models [38]. Addressing these adoption barriers requires a collaborative approach that demonstrates the long-term financial benefits of AI-driven optimization while ensuring regulatory and ethical compliance [39].

Future market projections indicate a growing interest in AI-enhanced pharmaceutical pricing, with increased investments in machine learning technologies for PBM optimization. Reports suggest that by 2030, AI-driven pricing models could account for up to 30% of all pharmaceutical pricing decisions, driven by advancements in predictive analytics and regulatory shifts toward value-based healthcare reimbursement systems [40]. Investment trends indicate a rising number of partnerships between AI technology firms and PBMs, aiming to develop transparent and efficient drug pricing algorithms that reduce unnecessary costs while maintaining market competitiveness [41].

To ensure stakeholder collaboration and long-term sustainability, AI-powered PBM models must be designed with flexibility and adaptability in mind. Establishing industry-wide best practices, including standardized AI auditing processes, regulatory compliance frameworks, and collaborative risk-sharing agreements between pharmaceutical companies and insurers, will be essential in fostering adoption [42]. Additionally, public-private partnerships that integrate AI-driven pricing with government-led healthcare initiatives can further promote affordability and accessibility, ensuring that dynamic pricing strategies align with broader healthcare policy objectives [43].

Overall, while AI-driven PBM models present a transformative opportunity to optimize pharmaceutical pricing, their widespread implementation will require overcoming regulatory, ethical, and market-related challenges. By developing transparent, compliant, and patient-centric pricing frameworks, the healthcare industry can harness AI's potential to improve affordability, reduce financial inefficiencies, and enhance equitable access to medications across diverse populations [44].



Figure 3 Regulatory and Ethical Considerations in AI-Powered Drug Pricing [22]

7. Future prospects and recommendations

7.1. Innovations in AI-Powered Pricing and Cost Optimization

The integration of AI-powered predictive analytics in pharmaceutical pricing is transforming cost optimization and formulary management. Predictive AI models analyze historical pricing trends, patient adherence data, and healthcare spending patterns to forecast future drug costs with high accuracy [25]. These models enable insurers and pharmacy benefit managers (PBMs) to dynamically adjust formulary placements, ensuring that the most cost-effective and therapeutically beneficial medications receive preferential pricing [26]. AI-driven cost forecasting also helps pharmaceutical manufacturers anticipate market fluctuations, allowing them to optimize pricing strategies that balance affordability with profitability [27].

One of the emerging innovations in AI-driven pharmaceutical pricing is the use of blockchain and smart contracts for PBM collaborations. Blockchain technology enhances pricing transparency by providing an immutable ledger of transactions between drug manufacturers, PBMs, insurers, and pharmacies, ensuring that negotiated rebates and discounts are fairly allocated across the supply chain [28]. Smart contracts automate pricing adjustments based on predefined conditions, such as adherence rates, patient income levels, or formulary updates, reducing administrative inefficiencies and eliminating pricing discrepancies [29]. These blockchain-enabled frameworks allow real-time verification of drug price adjustments, reducing fraudulent pricing practices and increasing trust among stakeholders [30].

Additionally, AI-powered automation is improving formulary updates by continuously assessing real-world data on drug efficacy, patient responses, and market demand. By integrating machine learning models with electronic health records, PBMs can adjust pricing structures based on real-time clinical insights, ensuring that high-value medications remain accessible while optimizing cost-efficiency across the pharmaceutical supply chain [31]. As AI capabilities continue to advance, future developments in AI-driven pricing strategies will likely include more personalized cost-sharing mechanisms, real-time pricing updates, and further automation of contract negotiations between PBMs and manufacturers [32].

7.2. Policy and Governance Recommendations for AI-PBM Integration

To ensure fairness, compliance, and ethical deployment of AI in pharmaceutical pricing, regulatory frameworks must evolve alongside technological advancements. Policymakers should establish guidelines that mandate AI transparency in drug pricing models, requiring PBMs and insurers to disclose the algorithms and data sources used to determine price adjustments [33]. This transparency would help mitigate concerns about algorithmic bias, ensuring that AI-driven pricing decisions do not disproportionately impact vulnerable patient populations [34].

Another key policy recommendation is the implementation of standardized AI auditing processes within the pharmaceutical industry. Regulatory bodies, such as the FDA and the Federal Trade Commission (FTC), should develop certification protocols for AI-powered pricing models, ensuring that these systems comply with ethical standards and do not engage in anti-competitive practices [35]. These auditing processes should include independent third-party reviews of AI decision-making frameworks, ensuring that pricing adjustments are based on objective clinical and economic factors rather than profit-driven motives [36].

To increase price transparency in AI-powered PBM pricing models, policymakers should also require real-time pricing disclosures for patients and healthcare providers. By mandating digital platforms that provide real-time drug pricing comparisons, patients can make informed decisions about their medication costs before filling prescriptions [37]. Additionally, PBMs should be required to disclose the full breakdown of manufacturer rebates and negotiated discounts, ensuring that cost savings are passed on to consumers rather than retained as excess revenue by intermediaries [38].

A final policy consideration is the need for stronger consumer protections against price manipulation in AI-driven pricing models. While AI optimizes pricing efficiency, there is a risk that unchecked algorithmic adjustments could lead to discriminatory pricing practices or market volatility. Policymakers should introduce safeguards that prevent excessive price fluctuations based on AI-generated projections, ensuring that pricing stability is maintained for essential medications [39]. By implementing these regulatory and governance measures, AI-powered pharmaceutical pricing can be leveraged to enhance affordability, transparency, and accessibility without compromising ethical integrity [40].

7.3. Conclusion and Final Remarks

The integration of AI into pharmaceutical pricing represents a transformative shift in cost optimization, patient adherence improvement, and PBM efficiency. AI-driven predictive analytics enable real-time price adjustments, optimizing medication affordability while ensuring market stability. Blockchain technology and smart contracts further enhance transparency, reducing inefficiencies in PBM collaborations and improving rebate allocation processes [41]. By leveraging AI-powered automation, formulary updates and cost adjustments can be dynamically optimized, ensuring that high-value medications remain accessible to patients across diverse economic backgrounds [42].

Despite these innovations, regulatory and ethical challenges must be addressed to ensure fair AI deployment in drug pricing. Policymakers must implement governance frameworks that mandate transparency, AI auditing, and consumer protection measures to prevent algorithmic biases and excessive pricing fluctuations. Increasing real-time pricing transparency and enforcing accountability in PBM negotiations will be critical in ensuring that AI-driven pharmaceutical pricing benefits both consumers and healthcare providers [43].

Continued research and industry collaboration will be essential in advancing AI-powered pricing models that balance affordability with financial sustainability. As AI technologies evolve, stakeholders across the pharmaceutical industry must work together to refine dynamic pricing strategies that improve accessibility without compromising market efficiency. By prioritizing innovation, regulatory oversight, and ethical implementation, AI-driven pharmaceutical pricing has the potential to revolutionize medication affordability and enhance long-term health outcomes for patients worldwide [44].

Table 3 Summary of Key Findings and Strategic Recommendations for AI-Driven Pricing Models

Key Findings	Strategic Recommendations
AI-powered dynamic pricing improves medication affordability and adherence.	Expand AI adoption for real-time cost adjustments based on patient financial data and adherence patterns.
AI-enhanced PBM contracts increase transparency and reduce inefficiencies in drug pricing negotiations.	Implement AI-driven rebate tracking and formulary decision-making to ensure fair pricing and direct patient cost benefits.

Blockchain and smart contracts strengthen drug pricing transparency and rebate distribution.	Encourage integration of blockchain technology in PBM operations to eliminate pricing opacity and improve contract compliance.
Tiered copay structures, optimized through AI, ensure equitable pricing models for diverse patient populations.	Develop AI-driven copay assistance programs to support financially vulnerable patients and improve long-term adherence.
AI-driven analytics reduce drug pricing disparities by aligning costs with treatment value and patient outcomes.	Promote regulatory policies that enforce AI fairness, prevent price manipulation, and standardize ethical AI pricing frameworks.
AI-integrated cost-sharing mechanisms lower financial burdens for high-risk patients.	Foster public-private partnerships to expand AI-driven financial assistance programs for essential medications.

By implementing these strategic recommendations, healthcare stakeholders can maximize the potential of AI-driven pharmaceutical pricing, ensuring sustainable, transparent, and patient-centered cost optimization in the years to come.

8. Conclusion

Recap of Key Contributions of AI-Driven Pricing Models

AI-driven pricing models have significantly reshaped pharmaceutical cost optimization by leveraging predictive analytics, real-time data processing, and dynamic pricing mechanisms. Unlike traditional fixed pricing structures, AI models enable continuous cost adjustments based on patient financial capabilities, medication adherence patterns, and evolving market trends. By integrating AI into drug pricing frameworks, insurers and pharmacy benefit managers (PBMs) can provide more flexible and equitable pricing, ensuring that essential medications remain accessible to diverse patient populations.

One of the primary contributions of AI-driven pricing is its ability to enhance affordability without compromising industry sustainability. AI-powered predictive analytics assess demand fluctuations and patient risk factors, allowing for cost optimization strategies that balance revenue considerations with affordability goals. These pricing models have demonstrated measurable improvements in adherence rates by reducing financial burdens, particularly for patients with chronic conditions such as diabetes and cardiovascular diseases. Furthermore, AI-based tiered copay structures have allowed for personalized cost adjustments, ensuring that lower-income individuals receive financial assistance while maintaining long-term medication adherence.

Additionally, AI's integration with blockchain and smart contracts has improved pricing transparency and rebate distribution. By automating pricing adjustments and formulary placements, these innovations mitigate inefficiencies associated with traditional PBM pricing negotiations. AI-enhanced cost-sharing mechanisms also enable dynamic adjustments in medication prices based on real-world treatment outcomes, creating a value-based pricing system that benefits both patients and healthcare providers.

The Transformative Role of AI-Enhanced PBM Contracting

AI-driven PBM contracting represents a significant step forward in reducing drug pricing disparities. Traditional PBM models often lack transparency, leading to unclear rebate structures, opaque formulary decisions, and inconsistent drug pricing. AI-powered contract optimization addresses these challenges by leveraging machine learning algorithms to analyze past negotiations, market data, and drug efficacy records, ensuring that pricing decisions are evidence-based and data-driven.

One of the most impactful changes facilitated by AI-enhanced PBM contracting is the real-time adjustment of rebate allocations. Unlike static contracts that lock in pricing based on outdated market conditions, AI allows for continuous updates in pricing agreements, aligning costs with current supply chain dynamics and patient adherence trends. This flexibility ensures that negotiated savings benefit patients directly, rather than being retained as surplus revenue by intermediaries.

Furthermore, AI-driven PBM models enhance formulary decision-making by integrating clinical outcome data and adherence analytics. This ensures that high-value, cost-effective medications are prioritized for reimbursement while discouraging overuse of high-cost drugs with marginal therapeutic benefits. By refining formulary placement through AI, PBMs can create a more equitable pricing landscape that improves access while reducing unnecessary expenditures.

Final Thoughts on the Future of AI-Powered Pricing in the Pharmaceutical Industry

As AI continues to advance, its role in pharmaceutical pricing is expected to expand, creating a more adaptive and efficient drug cost ecosystem. Future AI-driven models will likely incorporate real-time patient monitoring to predict adherence risks and adjust pricing structures accordingly. Enhanced integration with blockchain technology will further improve transparency, ensuring that drug pricing remains fair, competitive, and accessible to all patient groups.

The broader adoption of AI in pricing strategies will require collaborative efforts between policymakers, healthcare providers, and pharmaceutical companies. Regulatory frameworks must evolve to accommodate AI-driven decision-making while enforcing safeguards against algorithmic bias and unfair pricing practices. Additionally, continued investment in AI research will be necessary to refine predictive analytics, improve risk assessment models, and enhance AI's role in patient-centered pricing.

Ultimately, AI-driven pharmaceutical pricing has the potential to address long-standing affordability challenges, reduce disparities in drug access, and improve healthcare outcomes. By prioritizing transparency, fairness, and innovation, the pharmaceutical industry can harness AI's transformative power to create a pricing system that balances economic sustainability with patient well-being.

Compliance with ethical standards

Disclosure of conflict of interest

No conflict of interest to be disclosed.

References

[1] Grabowski H, Mullins CD. Pharmacy benefit management, cost-effectiveness analysis and drug formulary decisions. Social science & medicine. 1997 Aug 1;45(4):535-44.

[2] Paich M, Peck C, Valant J. Pharmaceutical market dynamics and strategic planning: a system dynamics perspective. System Dynamics Review. 2011 Jan;27(1):47-63.

[3] Huskamp HA, Rosenthal MB, Frank RG, Newhouse JP. The Medicare Prescription Drug Benefit: How Will The Game Be Played? A nuts-and-bolts proposal for using competition and pharmacy benefit managers to contain drug costs and promote quality. Health Affairs. 2000 Mar;19(2):8-23.

[4] Schoonveld E. The price of global health: drug pricing strategies to balance patient access and the funding of innovation. Routledge; 2016 Feb 24.

[5] van Boven JF, Ryan D, Eakin MN, Canonica GW, Barot A, Foster JM, Respiratory Effectiveness Group. Enhancing respiratory medication adherence: the role of health care professionals and cost-effectiveness considerations. The Journal of Allergy and Clinical Immunology: In Practice. 2016 Sep 1;4(5):835-46.

[6] Desselle SP, Moczygemba LR, Coe AB, Hess K, Zgarrick DP. Applying contemporary management principles to implementing and evaluating value-added pharmacist services. Pharmacy. 2019 Jul 20;7(3):99.

[7] Berndt ER, Newhouse JP. Pricing and reimbursement in US pharmaceutical markets. National Bureau of Economic Research; 2010 Aug 19.

[8] Rough S, Shane R, Armitstead JA, Belford SM, Brummond PW, Chen D, Collins CM, Dalton H, Dopp AL, Estevez MM, Hager DR. The high-value pharmacy enterprise framework: advancing pharmacy practice in health systems through a consensus-based, strategic approach. American Journal of Health-System Pharmacy. 2021 Mar 15;78(6):498-510.

[9] Valverde-Merino MI, Martinez-Martinez F, Garcia-Mochon L, Benrimoj SI, Malet-Larrea A, Perez-Escamilla B, Zarzuelo MJ, Torres-Robles A, Gastelurrutia MA, Varas-Doval R, Peiro Zorrilla T. Cost–Utility Analysis of a Medication Adherence Management Service Alongside a Cluster Randomized Control Trial in Community Pharmacy. Patient preference and adherence. 2021 Oct 24:2363-76.

[10] Kolassa EM. Elements of pharmaceutical pricing. CRC Press; 1997 Sep 19.

[11] Mensa Sorato M, Davari M, Abdollahi Asl A, Soleymani F, Kebriaeezadeh A. Why healthcare market needs government intervention to improve access to essential medicines and healthcare efficiency: a scoping review from pharmaceutical price regulation perspective. Journal of Pharmaceutical Health Services Research. 2020 Nov;11(4):321-33.

[12] Paolella GA, Boyd AD, Wirth SM, Cuellar S, Venepalli NK, Crawford SY. Adherence to oral anticancer medications: evolving interprofessional roles and pharmacist workforce considerations. Pharmacy. 2018 Mar 8;6(1):23.

[13] Ferreri SP, Hughes TD, Snyder ME. Medication therapy management: current challenges. Integrated Pharmacy Research and Practice. 2020 Apr 2:71-81.

[14] Atreja A, Bellam N, Levy SR. Strategies to enhance patient adherence: making it simple. Medscape General Medicine. 2005 Mar 15;7(1):4.

[15] Davies NM, Smith GD, Windmeijer F, Martin RM. Issues in the reporting and conduct of instrumental variable studies: a systematic review. Epidemiology. 2013 May 1;24(3):363-9.

[16] Alatorre C, Fernández Landó L, Yu M, Brown K, Montejano L, Juneau P, Mody R, Swindle R. Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: H igher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide. Diabetes, Obesity and Metabolism. 2017 Jul;19(7):953-61.

[17] Joseph Chukwunweike, Andrew Nii Anang, Adewale Abayomi Adeniran and Jude Dike. Enhancing manufacturing efficiency and quality through automation and deep learning: addressing redundancy, defects, vibration analysis, and material strength optimization Vol. 23, World Journal of Advanced Research and Reviews. GSC Online Press; 2024. Available from: https://dx.doi.org/10.30574/wjarr.2024.23.3.2800

[18] Chukwunweike JN, Praise A, Bashirat BA, 2024. Harnessing Machine Learning for Cybersecurity: How Convolutional Neural Networks are Revolutionizing Threat Detection and Data Privacy. https://doi.org/10.55248/gengpi.5.0824.2402.

[19] Curtis SE, Boye KS, Lage MJ, Garcia-Perez LE. Medication adherence and improved outcomes among patients with type 2 diabetes. Am J Manag Care. 2017 Jul 1;23(7):e208-14.

[20] Gerald Nwachukwu. Enhancing credit risk management through revalidation and accuracy in financial data: The impact of credit history assessment on procedural financing. International Journal of Research Publication and Reviews. 2024 Nov;5(11):631–644. Available from: https://ijrpr.com/uploads/V5ISSUE11/IJRPR34685.pdf.

[21] Ofili BT, Obasuyi OT, Akano TD. Edge Computing, 5G, and Cloud Security Convergence: Strengthening USA's Critical Infrastructure Resilience. *Int J Comput Appl Technol Res.* 2023;12(9):17-31. doi:10.7753/IJCATR1209.1003.

[22] Dugbartey AN. Systemic financial risks in an era of geopolitical tensions, climate change, and technological disruptions: Predictive analytics, stress testing and crisis response strategies. International Journal of Science and Research Archive. 2025;14(02):1428-1448. Available from: https://doi.org/10.30574/ijsra.2025.14.2.0563.

[23] Gourzoulidis G, Kourlaba G, Stafylas P, Giamouzis G, Parissis J, Maniadakis N. Association between copayment, medication adherence and outcomes in the management of patients with diabetes and heart failure. Health Policy. 2017 Apr 1;121(4):363-77.

[24] Omopariola BJ, Aboaba V. Comparative analysis of financial models: Assessing efficiency, risk, and sustainability. Int J Comput Appl Technol Res. 2019;8(5):217-231. Available from: https://ijcat.com/archieve/volume8/issue5/ijcatr08051013.pdf

[25] Gillespie CW, Morin PE, Tucker JM, Purvis L. Medication adherence, health care utilization, and spending among privately insured adults with chronic conditions in the United States, 2010-2016. The American Journal of Medicine. 2020 Jun 1;133(6):690-704.

[26] Kehinde O. Achieving strategic excellence in healthcare projects: Leveraging benefit realization management framework. World J Adv Res Rev. 2024;21(1):2925-2950. Available from: https://doi.org/10.30574/wjarr.2024.21.1.0034.

[27] Pednekar P, Heller DA, Peterson AM. Association of medication adherence with hospital utilization and costs among elderly with diabetes enrolled in a state pharmaceutical assistance program. Journal of Managed Care & Specialty Pharmacy. 2020 Sep;26(9):1099-108.

[28] Otoko J. Multi-objective optimization of cost, contamination control, and sustainability in cleanroom construction: A decision-support model integrating Lean Six Sigma, Monte Carlo Simulation, and Computational Fluid Dynamics (CFD). Int J Eng Technol Res Manag. 2023;7(1):108. Available from: https://doi.org/10.5281/zenodo.14950511

[29] Jiang Y, Ni W. Estimating the impact of adherence to and persistence with atypical antipsychotic therapy on health care costs and risk of hospitalization. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2015 Sep;35(9):813-22.

[30] Dave D, Dench D, Grossman M, Kenkel DS, Saffer H. Does e-cigarette advertising encourage adult smokers to quit?. Journal of Health Economics. 2019 Dec 1;68:102227.

[31] Perez-Nieves M, Boye KS, Kiljanski J, Cao D, Lage MJ. Adherence to basal insulin therapy among people with type 2 diabetes: a retrospective cohort study of costs and patient outcomes. Diabetes Therapy. 2018 Jun;9:1099-111.

[32] Banerji MA, Dunn JD. Impact of glycemic control on healthcare resource utilization and costs of type 2 diabetes: current and future pharmacologic approaches to improving outcomes. American health & drug benefits. 2013 Sep;6(7):382.

[33] Carls GS, Roebuck MC, Brennan TA, Slezak JA, Matlin OS, Gibson TB. Impact of medication adherence on absenteeism and short-term disability for five chronic diseases. Journal of occupational and environmental medicine. 2012 Jul 1;54(7):792-805.

[34] Aronson BD, Sittner KJ, Walls ML. The mediating role of diabetes distress and depressive symptoms in type 2 diabetes medication adherence gender differences. Health Education & Behavior. 2020 Jun;47(3):474-82.

[35] Eby EL, Bajpai S, Faries DE, Haynes VS, Lage MJ. The association between adherence to insulin therapy and health care costs for adults with type 2 diabetes: evidence from a US retrospective claims database. Journal of Managed Care & Specialty Pharmacy. 2020 Sep;26(9):1081-9.

[36] Rahman W, Solinsky PJ, Munir KM, Lamos EM. Pharmacoeconomic evaluation of sodium-glucose transporter-2 (SGLT2) inhibitors for the treatment of type 2 diabetes. Expert opinion on pharmacotherapy. 2019 Jan 22;20(2):151-61.

[37] Bilger M, Shah M, Tan NC, Tan CY, Bundoc FG, Bairavi J, Finkelstein EA. Process-and outcome-based financial incentives to improve self-management and glycemic control in people with type 2 diabetes in Singapore: a randomized controlled trial. The Patient-Patient-Centered Outcomes Research. 2021 Sep;14:555-67.

[38] Choi S. Experiencing financial hardship associated with medical bills and its effects on health care behavior: a 2-year panel study. Health Education & Behavior. 2018 Aug;45(4):616-24.

[39] Bernard D, Fang Z. Financial burdens and barriers to care among nonelderly adults with heart disease: 2010–2015. Journal of the American Heart Association. 2019 Dec 17;8(24):e008831.

[40] Di Novi C, Leporatti L, Montefiori M. Older patients and geographic barriers to pharmacy access: When nonadherence translates to an increased use of other components of health care. Health economics. 2020 Oct;29:97-109.

[41] Shi J, Yang W, Yuan Y. Cover more for less: Targeted drug coverage, chronic disease management, and medical spending. Journal of Development Economics. 2025 Jan 1;172:103399.

[42] Pawaskar MD, Xu L, Tang Y, Puckrein GA, Rajpathak SN, Stuart B. Effect of medication copayment on adherence and discontinuation in Medicare beneficiaries with type 2 diabetes: a retrospective administrative claims database analysis. Diabetes Therapy. 2018 Oct;9:1979-93.

[43] Stuart BC, Dai M, Xu J, Loh FH, Dougherty JS. Does good medication adherence really save payers money?. Medical care. 2015 Jun 1;53(6):517-23.

[44] Parasrampuria S. Comparing patient OOP spending for specialty drugs in Medicare Part D and employer-sponsored insurance. The American Journal of Managed Care. 2020 Sep 11;26(9).